Item 8.01 Other Events.
On January 6, 2022, Zai Lab Limited issued a press release announcing that the
China National Medical Products Administration has accepted the new drug
application (NDA) for margetuximab, an investigational, Fc-engineered monoclonal
antibody that targets HER2. The margetuximab NDA is for the treatment of adult
patients with metastatic HER2-positive breast cancer who have received two or
more prior anti-HER2 regimens, at least one of which was for metastatic disease,
in combination with chemotherapy. A copy of the press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press Release issued by Zai Lab Limited on January 6, 2022.
104 The cover page of this Current Report on Form 8-K is formatted in
Inline XBRL
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses